OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone267-364-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$47.50 million
Profitability
Miscellaneous
Employees82
OptionableNot Optionable
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) announced its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.77) by $0.13. The company earned $1.27 million during the quarter, compared to analysts' expectations of $1.01 million. View OptiNose's Earnings History.
When is OptiNose's next earnings date?
What price target have analysts set for OPTN?
3 brokers have issued 1 year price targets for OptiNose's shares. Their forecasts range from $27.00 to $30.00. On average, they expect OptiNose's share price to reach $28.3333 in the next twelve months. This suggests a possible upside of 282.9% from the stock's current price. View Analyst Price Targets for OptiNose.
What is the consensus analysts' recommendation for OptiNose?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.
What are Wall Street analysts saying about OptiNose stock?
Here are some recent quotes from research analysts about OptiNose stock:
- 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (2/13/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $27 price target for OPTN stock. We believe the slower than forecast ramp in Xhance launch is reflected in the current stock price. Given the reset, we believe OPTN stock presents a compelling entry point and risk/reward profile. We remain bullish on the peak sales potential for Xhance, and while we are conservative on near term sales, we believe Xhance will exceed long term expectations, and thus drive upside to OPTN stock." (2/4/2019)
Has OptiNose been receiving favorable news coverage?
News stories about OPTN stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OptiNose earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Phibro Animal Health (PAHC), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Kiniksa Pharmaceuticals (KNSA), Alder Biopharmaceuticals (ALDR), Tricida (TCDA), Advanz Pharma (CXRXF), MacroGenics (MGNX), Retrophin (RTRX) and Homology Medicines (FIXX).
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 58)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 47)
When did OptiNose IPO?
(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.
Who are OptiNose's major shareholders?
OptiNose's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.41%), Foresite Capital Management IV LLC (4.14%), Thrivent Financial for Lutherans (3.34%), Massachusetts Financial Services Co. MA (2.11%), Broadfin Capital LLC (1.72%) and Kornitzer Capital Management Inc. KS (1.16%). Company insiders that own OptiNose stock include Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.
Which institutional investors are selling OptiNose stock?
OPTN stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Bank of New York Mellon Corp, Millennium Management LLC and New York State Common Retirement Fund. View Insider Buying and Selling for OptiNose.
Which institutional investors are buying OptiNose stock?
OPTN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Broadfin Capital LLC, Kornitzer Capital Management Inc. KS, Foresite Capital Management IV LLC, Amundi Pioneer Asset Management Inc., Prosight Management LP, Two Sigma Investments LP and Thrivent Financial for Lutherans. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $7.40.
How big of a company is OptiNose?
OptiNose has a market capitalization of $305.09 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.
What is OptiNose's official website?
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (NASDAQ OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
